Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Post-transplant Lymphoproliferative Disease”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01575860
What this trial is testing

Maintenance Lenalidomide in Lymphoma

Who this might be right for
Lymphoma
Abramson Cancer Center at Penn Medicine 8
Testing effectiveness (Phase 2)UnknownNCT03540849
What this trial is testing

BV After Allogeneic Hematopoietic Stem Cell Transplantation

Who this might be right for
Hodgkin Lymphoma
University Hospital, Caen 58
Early research (Phase 1)Study completedNCT00477035
What this trial is testing

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

Who this might be right for
LeukemiaMultiple Myeloma
Sally Arai 22
Early research (Phase 1)Study completedNCT00361049
What this trial is testing

Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant

Who this might be right for
Cancer
Case Comprehensive Cancer Center 49
Large-scale testing (Phase 3)Study completedNCT03959241
What this trial is testing

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

Who this might be right for
Acute LeukemiaChronic Myelogenous Leukemia (CML)Myelodysplasia+1 more
Medical College of Wisconsin 431
Testing effectiveness (Phase 2)Study completedNCT00622388
What this trial is testing

Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant

Who this might be right for
Lymphoma, Large-Cell, Diffuse
GlaxoSmithKline 81
Early research (Phase 1)Study completedNCT03383055
What this trial is testing

CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig

Who this might be right for
LymphomaMultiple Myeloma
Masonic Cancer Center, University of Minnesota 28
Testing effectiveness (Phase 2)WithdrawnNCT00577668
What this trial is testing

A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)

Who this might be right for
Multiple Myeloma
University of Arkansas
Testing effectiveness (Phase 2)Enrolling By InvitationNCT06931613
What this trial is testing

Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment

Who this might be right for
Relapsed or Refractory Hodgkin LymphomaChildrenNivolumab+1 more
St. Petersburg State Pavlov Medical University 20
Large-scale testing (Phase 3)Ended earlyNCT00256776
What this trial is testing

MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation

Who this might be right for
Multiple Myeloma
European Society for Blood and Marrow Transplantation 269
Testing effectiveness (Phase 2)Study completedNCT01562990
What this trial is testing

Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse

Who this might be right for
Diffuse Large B-Cell Lymphoma
The Lymphoma Academic Research Organisation 11
Testing effectiveness (Phase 2)WithdrawnNCT03982992
What this trial is testing

Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab

Who this might be right for
B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell TransplantationB-Cell Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia+2 more
Ludwig-Maximilians - University of Munich
Testing effectiveness (Phase 2)Study completedNCT02572167
What this trial is testing

Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
Seagen Inc. 93
Not applicableStudy completedNCT03106324
What this trial is testing

A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

Who this might be right for
Multiple Myeloma
Celgene 911
Early research (Phase 1)Ended earlyNCT01750762
What this trial is testing

Lenalidomide After Allo Transplant

Who this might be right for
Multiple MyelomaLymphoma
Beth Israel Deaconess Medical Center 1
Testing effectiveness (Phase 2)Ended earlyNCT00143884
What this trial is testing

Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood

Who this might be right for
LeukemiaLymphoma, Low-GradeLymphoma, Non-Hodgkin's+2 more
University of Michigan Rogel Cancer Center 30
Not applicableEnded earlyNCT00215033
What this trial is testing

Relationship Between EBV and PTLD

Who this might be right for
Pediatric Heart Transplant
Children's Healthcare of Atlanta 160
Testing effectiveness (Phase 2)UnknownNCT05054465
What this trial is testing

A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL

Who this might be right for
Acute Lymphoblastic Leukemia
Israeli Medical Association 48
Testing effectiveness (Phase 2)Study completedNCT01058239
What this trial is testing

Bortezomib Plus Rituximab for EBV+ PTLD

Who this might be right for
Post-transplant Lymphoproliferative DiseaseSolid Organ TransplantStem Cell Transplant (Bone Marrow Transplant)+1 more
Massachusetts General Hospital 7
Testing effectiveness (Phase 2)Ended earlyNCT02991898
What this trial is testing

Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies

Who this might be right for
Acute Lymphoblastic LeukemiaBurkitt LymphomaNatural Killer Cell Malignancies+15 more
Masonic Cancer Center, University of Minnesota 3
Next Page